EN DE
Watch Hyperion DeFi, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hyperion DeFi, Inc. (HYPD) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Hyperion DeFi, Inc. stock $2.22, price $2.59, that is 14.3% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

HD Hyperion DeFi, Inc. logo Thin data Nov 10, 2026

Hyperion DeFi, Inc.

HYPD · US
Expensive, weak quality

Our calculation puts a fair price 14% below what the stock costs today.

Low debt
Revenue last quarter +16% vs. a year ago.
Mixed vs. peers (3/7)
Insiders bought $29,580 (6M)
Fair value $2.22 · Overvalued
Quality 28/100
Weak Growth (revenue 5y −16.5 %/yr in USD)
Negative free cash flow
Narrow moat 29/100 · thin data
Thin data
Estimate
Watch Hyperion DeFi, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$526.40 $0.9200 Fair Value $2.22 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.9200 – $526.40 · fair‑value band $1.66 – $2.77 · the $2.59 price screens above the $2.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Hyperion DeFi in your weekly email

Every Wednesday you see whether Hyperion DeFi is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem.

Show moreShow less

It is also developing the Optejet User Filled Device to work with various topical ophthalmic liquids, including artificial tears and lens rewetting products. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025.

Hyperion DeFi, Inc. was founded in 2014 and is based in Dallas, Texas.

Stock analysis

Hyperion DeFi, Inc. (HYPD) currently trades at $2.59, while our estimate is $2.22, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.66 (bear) to $2.77 (bull), the price of $2.59 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Hyperion DeFi, Inc. reported revenue of $813K in FY2025 versus $14.0M in FY2021, a compound −50.9%/yr. Reported net income was −$45.3M in FY2025.

Key figures

Market cap $44.2M Micro · P/S ratio 32.6 · EPS (TTM) $−6.46 · Return on equity 9.6% · Return on assets (EBIT) −316% (5-year average) · Operating margin −758% · Revenue (TTM) $1.4M · Revenue growth (YoY) +15.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −14%, HYPD screens richer than that median.

Fair Value

Bear $1.66 Fair Value $2.22 Bull $2.77
Price $2.59 · Downside -14.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 90
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 36
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $29,580, on Jun 2, 2026.

  • BuyHyunsu JungOfficer, Director8,000 shares at $3.70$29,580Jun 2, 2026
  • BuyDavid R. KnoxChief Financial Officer27,950 shares at $3.59$100,341Dec 31, 2025
  • BuyEllen R StrahlmanDirector2× since Dec 18, 2025: 69,324 shares, avg. $3.37$233,798Dec 29, 2025
  • BuyMichael S GeltzeilerDirector30,000 shares at $3.01$90,300Dec 17, 2025
  • BuyHappy David WaltersDirector61,930 shares at $3.02$187,029Dec 17, 2025

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 15/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1,318.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.5%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−989.5% (2020) → −2,333.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

HYPD screens overvalued: fair value 14% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Hyperion DeFi, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −14.3% · Above median
Profitability
Return on equity (12 months) 9.6% · Top 25%
Return on assets −87.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 15.6% · Above median
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.08× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 31.56× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)14 · sector 0
FUTURE (revenue growth)78 · sector 0
PAST (return on equity)38 · sector 0
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs HYPD
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs HYPD
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs HYPD
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs HYPD
argenx SE ARGX $971.55 $908.40 −7% vs HYPD
CSL Limited CSL A$201.68 A$181.40 −10% vs HYPD
Moderna, Inc MRNA $250.83 $158.70 −37% vs HYPD
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs HYPD
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs HYPD
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs HYPD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hyperion DeFi, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hyperion DeFi, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/HYPD

Frequently asked questions

Is Hyperion DeFi, Inc. (HYPD) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $2.22 versus a price of $2.59, about 14% lower (overvalued).
What is the fair value of HYPD?
Our estimate for Hyperion DeFi, Inc. is $2.22 (as of Nov 10, 2026), built from audited fundamentals. The current price: $2.59.
What is the quality score of HYPD?
Hyperion DeFi, Inc. has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hyperion DeFi, Inc. (HYPD)?
Our calculated price target is the estimate of $2.22 (as of Nov 10, 2026). Cautious scenario $1.66, optimistic scenario $2.77. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Hyperion DeFi, Inc. stock forecast for 2026?
Our estimate puts fair value at $2.22, about 14% lower versus a price of $2.59 (overvalued). Cautious scenario $1.66, optimistic scenario $2.77. The calculation is refreshed regularly with new filings.
What is the revenue of Hyperion DeFi, Inc. (HYPD)?
Hyperion DeFi, Inc. reported trailing-twelve-month revenue of about $1.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Hyperion DeFi, Inc. (HYPD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hyperion DeFi, Inc. it is $2.22 per share (as of Nov 10, 2026), against a price of $2.59.
Is Hyperion DeFi, Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, HYPD trades above its calculated fair value: price $2.59, fair value $2.22, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HYPD?
No. The price is what the market pays today ($2.59); the fair value is what the company's own numbers justify ($2.22). For Hyperion DeFi, Inc. the two are $0.3700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hyperion DeFi, Inc. worth?
The market values Hyperion DeFi, Inc. at about $44.2M (market capitalisation, as of Nov 10, 2026). Per share that is $2.59; our models calculate a fair value of $2.22 per share.
What do the bullish and bearish scenarios say about HYPD?
Our models span a range for Hyperion DeFi, Inc.: cautious scenario $1.66, base $2.22, optimistic $2.77 per share (as of Nov 10, 2026, price $2.59). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hyperion DeFi, Inc. (HYPD)?
Balance-sheet figures for Hyperion DeFi, Inc. (as of Nov 10, 2026): return on equity 9.6%, debt of 0.19 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is HYPD from its 52-week high?
Hyperion DeFi, Inc. trades at $2.59, about 55% below its 52-week high of $5.82 and 11% above the low of $2.34 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.22 is for.
Which stocks are comparable to Hyperion DeFi, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hyperion DeFi, Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $2.59, calculated fair value $2.22 (−14%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Hyperion DeFi, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hyperion DeFi, Inc. (HYPD)?
The closing price on Nov 10, 2026 was $2.59. Our estimate is $2.22, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hyperion DeFi, Inc. right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Hyperion DeFi, Inc.

How large is the market capitalisation of Hyperion DeFi, Inc. (HYPD)?
The market capitalisation of Hyperion DeFi, Inc. is $44.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hyperion DeFi, Inc. (HYPD)?
The price-to-sales ratio of Hyperion DeFi, Inc. is 32.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hyperion DeFi, Inc. (HYPD)?
Earnings per share at Hyperion DeFi, Inc. are $−6.46. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Hyperion DeFi, Inc. (HYPD)?
The return on equity (ROE) of Hyperion DeFi, Inc. is 9.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hyperion DeFi, Inc. (HYPD)?
On an EBIT basis the return on assets of Hyperion DeFi, Inc. is −316% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hyperion DeFi, Inc. (HYPD)?
The operating margin of Hyperion DeFi, Inc. is −758% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hyperion DeFi, Inc. (HYPD)?
Revenue at Hyperion DeFi, Inc. is growing +15.6% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hyperion DeFi, Inc. (HYPD) generate?
The free cash flow of Hyperion DeFi, Inc. is −$14.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hyperion DeFi, Inc. (HYPD) carry?
The net debt of Hyperion DeFi, Inc. is $2.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hyperion DeFi, Inc. in the live analysis

One click puts Hyperion DeFi, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.